Moderna confirmed discussions with the MHLW to supply Japan with 40 million doses of mRNA vaccine against COVID-19
On Aug. 28, 2020, Moderna confirmed that the Company was engaged in discussions with the Ministry of Health,…
Rapid diagnostic detected Lassa and Ebola in real-time
On Aug. 26, 2020, researchers announced an inexpensive, sensitive, CRISPR-based tests diagnose two deadly viruses in settings with…
How SARS-CoV-2 spread across greater Boston during pandemic’s first wave
On Aug. 25, 2020, data from the Broad Institute of MIT and Harvard, Massachusetts General Hospital, the Massachusetts…
Genomic analysis revealed many animal species may be vulnerable to SARS-CoV-2 infection
On Aug. 24, 2020, humans are not the only species facing a potential threat from SARS-CoV-2, the novel…
Evidence suggested children could play a larger role in community spread of COVID-19
On Aug. 20, 2020, in the most comprehensive study of COVID-19 pediatric patients to date, Harvard Medical School…
Johnson & Johnson acquired Momenta Pharmaceuticals for $65 billion
On Aug. 19, 2020, Johnson & Johnson announced an agreement to acquire Momenta Pharmaceuticals, a company that discovers…
Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19
On Aug. 11, 2020, Moderna announced that the U.S. government had secured 100 million doses of mRNA-1273. The…
NIH-Moderna investigational COVID-19 vaccine showed promise in mouse studies
On Aug. 5, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that the investigational vaccine…
Yale researchers part of new NSF-funded quantum center
On Aug. 4, 2020, Yale University announced it was among the core partners of the new Center for…
Moderna announced publication in the NEJM of non-human primate preclinical viral challenge study of its mRNA vaccine against COVID-19
On Jul. 28, 2020, Moderna announced a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published…
Phase 3 clinical trial of investigational vaccine for COVID-19 began
On Jul. 27, 2020, the National Institutes of Health (NIH) announced that a phase 3 clinical trial designed…
Moderna announced phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273) began
On Jul. 27, 2020, Moderna announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against…
Moderna announced expansion of BARDA agreement to support larger phase 3 program for vaccine (mRNA-1273) against COVID-19
On Jul. 26, 2020, Moderna announced a modification to its contract with the Biomedical Advanced Research and Development…
Experimental Coronavirus vaccine is safe and produced immune response
On Jul. 21, 2020, National Institutes of Health (NIH) researchers reported early results from the first COVID-19 vaccine…
Experimental coronavirus vaccine reported safe and produces immune response
On Jul. 21, 2020, researchers from the National Institutes of Health (NIH) announced that early results from the…
Moderna announced publication in The New England Journal of Medicine of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Jul. 14, 2020, Moderna announced the publication of an interim analysis of the open-label Phase 1 study…
Broad Institute launched academic-industry cell imaging consortium to speed drug discovery and development
On Jul. 10, 2020, the Imaging Platform at the Broad Institute of MIT and Harvard, together with industry…
Moderna and ROVI announced collaboration for OUS fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate
On Jul. 9, 2020 Moderna and Laboratorios Farmaceuticos Rovi announced a collaboration for large-scale, commercial fill-finish manufacturing of…
Moderna completed enrollment of phase 2 study of its mRNA vaccine against COVID-19 (mRNA-1273)
On Jul. 8, 2020, Moderna announced that it had completed enrollment for both cohorts of the Phase 2…
Constant Therapeutics’ TXA127 tested in multiple clinical trials for COVID-19 patients
On Jul. 8, 2020, Constant Therapeutics reported that its peptide drug TXA127 was tested in a series of…
Tonix Pharma announced plans for Massachusetts R&D facility to accelerate clinical development of vaccines and protein-based therapeutics
On Jul. 7, 2020, Tonix Pharmaceuticals announced its intent to purchase an approximately 40,000 square foot facility in…
Successful first harvest provided roadmap for scaling secure, domestic source of farm-raised salmon
On Jun. 30, 2020, AquaBounty Technologies announced it had successfully commenced the commercial-scale harvest of conventional Atlantic salmon…
Moderna and Catalent announced collaboration for fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate
On Jun. 25, 2020 Moderna announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine…
Moderna advanced late-stage development of vaccine (mRNA-1273) against COVID-19
On Jun. 11, 2020, Moderna announced progress on late-stage development of mRNA-1273, the Company’s mRNA vaccine candidate against…
Introduction and spread of SARS-CoV-2 in the greater Boston area
On Jun. 4, 2020, data from the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and the…
Moderna announced first participants in each age cohort dosed in phase 2 study of mRNA vaccine against novel Coronavirus
On May 29, 2020, Moderna announced the first participants in each age cohort had been dosed in the…
Biogen and MIT launched virtual learning lab for high school students historically underrepresented in science
On May 28, 2020, Biogen and the Lemelson-MIT Program (LMIT) at the Massachusetts Institute of Technology announced the…
Moderna announced positive interim phase 1 data for mRNA Vaccine against novel Coronavirus
On May 18, 2020, Moderna announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus…
Harvard-led initiative awarded over $165 million to support 62 COVID-19 research projects
On May 13, 2020, the Massachusetts Consortium on Pathogen Readiness (MassCPR), a multi-institutional initiative convened by Harvard Medical…
Moderna received FDA Fast Track Designation for mRNA vaccine (mRNA-1273) against novel Coronavirus
On May 12, 2020, Moderna announced the U.S. Food and Drug Administration (FDA had granted Fast Track designation…